OBJECTIVE: Overall about 10 to 20% of pheochromocytomas/paragangliomas (PHEOs/PGLs) are metastatic, with higher metastatic potential observed in succinate dehydrogenase subunit B/fumarate hydratase (SDHB/FH)-related tumors. Due to the improved availability of biochemical and genetic testing and the frequent use of anatomical/functional imaging, there is currently a higher detection rate of metastatic PHEO/PGL. METHODS: A retrospective analysis of 132 patients (27 children, 105 adults) with metastatic PHEO/PGL diagnosed and treated from 2000 to 2014 was conducted. RESULTS: Seventy-seven (58%) males and 55 (42%) females were included; 39 (30%) have died, with no sex preference. Seventy-three (55%) patients had SDHB mutations; 59 (45%) patients had apparently sporadic tumors (AST). SDHB patients had an average age at primary tumor diagnosis of 31 ± 16 years compared to 40 ± 15 years in AST patients (P<.001). The average metastatic interval (MI) decreased with increasing age in both SDHB and AST patients (P = .013 for both). Only 16% of all primary tumors were smaller than 4.5 cm. Eleven percent of patients had biochemically silent disease, more with SDHB. Of SDHB patients, 23% had metastatic tumors at first diagnosis, compared to 15% of AST patients. Five- and 10-year survival rates were significantly better for metastatic AST than SDHB patients (P = .01). Overall survival was significantly different between children and adults (P = .037); this was mostly attributed to the SDHB patients, in whom children had statistically significantly longer survival than adults (P = .006). The deceased patients all died due to the PHEO/PGL and mainly had noradrenergic phenotypes. CONCLUSION: In children, metastatic PHEOs/PGLs are mainly due to SDHB mutations; in adults they are equally distributed between in SDHB mutations and AST, with better 5- and 10-year survival rates for ASTs. In SDHB patients, children survive longer than adults. Primary metastatic tumors, most presenting as noradrenergic PGLs, are larger than 4.5 cm in >80% of patients. The frequency of metastatic tumors from primary AST increases with age, including a decreased MI compared to SDHB tumors. These results support several recommendations that are summarized in the Discussion.
OBJECTIVE: Overall about 10 to 20% of pheochromocytomas/paragangliomas (PHEOs/PGLs) are metastatic, with higher metastatic potential observed in succinate dehydrogenase subunit B/fumarate hydratase (SDHB/FH)-related tumors. Due to the improved availability of biochemical and genetic testing and the frequent use of anatomical/functional imaging, there is currently a higher detection rate of metastatic PHEO/PGL. METHODS: A retrospective analysis of 132 patients (27 children, 105 adults) with metastatic PHEO/PGL diagnosed and treated from 2000 to 2014 was conducted. RESULTS: Seventy-seven (58%) males and 55 (42%) females were included; 39 (30%) have died, with no sex preference. Seventy-three (55%) patients had SDHB mutations; 59 (45%) patients had apparently sporadic tumors (AST). SDHBpatients had an average age at primary tumor diagnosis of 31 ± 16 years compared to 40 ± 15 years in ASTpatients (P<.001). The average metastatic interval (MI) decreased with increasing age in both SDHB and ASTpatients (P = .013 for both). Only 16% of all primary tumors were smaller than 4.5 cm. Eleven percent of patients had biochemically silent disease, more with SDHB. Of SDHBpatients, 23% had metastatic tumors at first diagnosis, compared to 15% of ASTpatients. Five- and 10-year survival rates were significantly better for metastatic AST than SDHBpatients (P = .01). Overall survival was significantly different between children and adults (P = .037); this was mostly attributed to the SDHBpatients, in whom children had statistically significantly longer survival than adults (P = .006). The deceased patients all died due to the PHEO/PGL and mainly had noradrenergic phenotypes. CONCLUSION: In children, metastatic PHEOs/PGLs are mainly due to SDHB mutations; in adults they are equally distributed between in SDHB mutations and AST, with better 5- and 10-year survival rates for ASTs. In SDHBpatients, children survive longer than adults. Primary metastatic tumors, most presenting as noradrenergic PGLs, are larger than 4.5 cm in >80% of patients. The frequency of metastatic tumors from primary AST increases with age, including a decreased MI compared to SDHB tumors. These results support several recommendations that are summarized in the Discussion.
Authors: Graeme Eisenhofer; Jacques W M Lenders; Henri Timmers; Massimo Mannelli; Stefan K Grebe; Lorenz C Hofbauer; Stefan R Bornstein; Oliver Tiebel; Karen Adams; Gennady Bratslavsky; W Marston Linehan; Karel Pacak Journal: Clin Chem Date: 2011-01-24 Impact factor: 8.327
Authors: Dragana Milosevic; Patrick Lundquist; Kendall Cradic; Noemi Vidal-Folch; ThanhTruc Huynh; Karel Pacak; Stefan K G Grebe Journal: Clin Biochem Date: 2010-02-12 Impact factor: 3.281
Authors: Uma Shankavaram; Stephanie M J Fliedner; Abdel G Elkahloun; Jenifer J Barb; Peter J Munson; Thanh T Huynh; Joey C Matro; Hana Turkova; W Marston Linehan; Henri J Timmers; Arthur S Tischler; James F Powers; Ronald de Krijger; Bora E Baysal; Martina Takacova; Silvia Pastorekova; David Gius; Hendrik Lehnert; Kevin Camphausen; Karel Pacak Journal: Neoplasia Date: 2013-04 Impact factor: 5.715
Authors: Abhishek Jha; Alexander Ling; Corina Millo; Garima Gupta; Bruna Viana; Frank I Lin; Peter Herscovitch; Karen T Adams; David Taïeb; Adam R Metwalli; W Marston Linehan; Alessandra Brofferio; Constantine A Stratakis; Electron Kebebew; Maya Lodish; Ali Cahid Civelek; Karel Pacak Journal: Eur J Nucl Med Mol Imaging Date: 2017-12-04 Impact factor: 9.236
Authors: Ivana Jochmanova; April Melody T Abcede; Ruby Jane S Guerrero; Chandy Lou P Malong; Robert Wesley; Thanh Huynh; Melissa K Gonzales; Katherine I Wolf; Abhishek Jha; Marianne Knue; Tamara Prodanov; Naris Nilubol; Leilani B Mercado-Asis; Constantine A Stratakis; Karel Pacak Journal: J Cancer Res Clin Oncol Date: 2020-02-15 Impact factor: 4.553
Authors: Ingo Janssen; Clara C Chen; Corina M Millo; Alexander Ling; David Taieb; Frank I Lin; Karen T Adams; Katherine I Wolf; Peter Herscovitch; Antonio T Fojo; Inga Buchmann; Electron Kebebew; Karel Pacak Journal: Eur J Nucl Med Mol Imaging Date: 2016-03-21 Impact factor: 9.236
Authors: Yang Liu; Ying Pang; Chunzhang Yang; Karel Pacak; Boqun Zhu; Ondrej Uher; Veronika Caisova; Thanh-Truc Huynh; David Taieb; Katerina Hadrava Vanova; Hans Kumar Ghayee; Jiri Neuzil; Mark Levine Journal: Clin Cancer Res Date: 2020-03-09 Impact factor: 12.531